Adrenocortical carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
IGF2 role in adrenocortical carcinoma biology.
|
31378849 |
2019 |
Adrenocortical carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We previously demonstrated that, in adrenocortical carcinoma (ACC), ERα is upregulated and that estradiol activates the IGF-II/IGF1R signaling pathways defining the role of this functional cross-talk in H295R ACC cell proliferation.
|
29112114 |
2017 |
Adrenocortical carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Key molecular events that contribute to formation of adrenocortical cancer are IGF2 overexpression, TP53-inactivating mutations, and constitutive activation of the Wnt/b-catenin signalling pathway via activating mutations of the b-catenin gene.
|
27387247 |
2016 |
Adrenocortical carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Methylation of IGF2 regulatory regions to diagnose adrenocortical carcinomas.
|
27535174 |
2016 |
Adrenocortical carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
We have previously demonstrated that estrogen receptor (ER) alpha (ESR1) increases proliferation of adrenocortical carcinoma (ACC) through both an estrogen-dependent and -independent (induced by IGF-II/IGF1R pathways) manner.
|
26131713 |
2015 |
Adrenocortical carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Overexpression of insulin growth factor 2 (IGF2) is a hallmark of adrenocortical carcinomas and pheochromocytomas.
|
26400872 |
2015 |
Adrenocortical carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
IGF2 promotes growth of adrenocortical carcinoma cells, but its overexpression does not modify phenotypic and molecular features of adrenocortical carcinoma.
|
25089899 |
2014 |
Adrenocortical carcinoma
|
0.500 |
Biomarker
|
disease |
CTD_human |
Everolimus therapy for progressive adrenocortical cancer.
|
23417626 |
2013 |
Adrenocortical carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Abnormal methylation at the IGF2/H19 locus is common in adrenocortical carcinomas.
|
23093492 |
2013 |
Adrenocortical carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
p53 Stabilization induces cell growth inhibition and affects IGF2 pathway in response to radiotherapy in adrenocortical cancer cells.
|
23028800 |
2012 |
Adrenocortical carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Previous studies have identified overexpression of insulin-like growth factor 2 (IGF-2) and constitutive activation of β-catenin as key factors involved in the development of adrenocortical carcinoma.
|
21386792 |
2011 |
Adrenocortical carcinoma
|
0.500 |
Biomarker
|
disease |
CTD_human |
Clinicopathological features, biochemical and molecular markers in 5 patients with adrenocortical carcinoma.
|
21521927 |
2011 |
Adrenocortical carcinoma
|
0.500 |
AlteredExpression
|
disease |
LHGDN |
Otherwise, IGF-II was mainly overexpressed in adult adrenocortical carcinomas (270.5 +/- 130.2 vs. 16.1 +/- 13.3; P = 0.0001).
|
18611974 |
2008 |
Adrenocortical carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
IGF-II overexpression has been consistently demonstrated in adult adrenocortical carcinomas.
|
18611974 |
2008 |
Adrenocortical carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Because the overexpression of the IGF-II gene is a frequent feature of adrenal carcinoma, we searched for the presence of GHRH-R SVs in these tumours.
|
15853821 |
2005 |
Adrenocortical carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The genetic predisposition to adrenocortical cancer in children has been well established in the Li-Fraumeni and Beckewith-Wiedeman syndromes due to germline p53 mutation located at 17p13 and dysregulation of the imprinted IGF-2 locus at 11p15, respectively.
|
16001332 |
2005 |
Adrenocortical carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
It is evident, therefore, that high levels of IGF-II in combination with overexpression of the IGF-I-receptor can provide a significant growth advantage for adrenocortical carcinoma cells and thus contribute to the highly malignant phenotype of this rare type of cancer.
|
15241731 |
2004 |
Adrenocortical carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
RNA analysis indicated that the adrenocortical carcinomas expressed less H19 but more IGF-II RNAs than normal adrenal tissues did.
|
11889182 |
2002 |
Adrenocortical carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The xenografts precisely reproduced the dysregulation of the insulin-like growth factor (IGF) system [overexpression of the IGF-II and IGF-binding protein-2 (IGFBP-2) genes] typical of adrenocortical carcinoma.
|
10965887 |
2000 |
Adrenocortical carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Autocrine role of IGF-II in proliferation of human adrenocortical carcinoma NCI H295R cell line.
|
10425444 |
1999 |
Adrenocortical carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Hormonally active adrenocortical carcinomas and virilizing adenomas express insulin-like growth factor II gene abundantly.
|
9694575 |
1998 |
Adrenocortical carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
IGF2 is often overexpressed in many tumours including adrenal carcinomas.
|
9367863 |
1997 |
Adrenocortical carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The decreased expression of both p57KIP2 and H19 RNAs in conjunction with elevated IGF-II mRNA expression in hormonally active adrenocortical carcinomas suggests that the loss of expression of the putative tumor suppressor genes p57KIP2 and H19 may be involved in the pathogenesis of these neoplasms.
|
9177379 |
1997 |
Adrenocortical carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
In four hormonally active adrenocortical carcinomas, very low levels of H19 ribonucleic acid (RNA) were detected, whereas IGF-II was highly expressed.
|
7531713 |
1995 |
Adrenocortical carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
IGF-II mRNA levels were more than 10-fold higher in hormonally active adrenocortical carcinomas than in normal adult adrenals, and increased IGF-II-like immunoreactivity was detectable in these carcinomas.
|
8370710 |
1993 |